Clinical Trial Update: Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating icotinib as consolidation therapy after chemoradiotherapy in EGFR-mutant stage IIIA-IIIB non-small cell lung cancer; current status is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• icotinib (icotinib)

Snippet

Sponsor: Betta Pharmaceuticals Co., Ltd. | Conditions: EGFR Gene Mutation, Non Small Cell Lung Cancer Stage IIIA | Phase 2 | Status: UNKNOWN